🫀Is there still a role for low-dose #digoxin in modern HF therapy? Primary results from the #DECISION trial presented by Prof. Dirk van Veldhuisen at #HeartFailure26: 📍Low-dose digoxin did not significantly ⬇️ the primary composite endpoint of CV mortality + total worsening HF events 📍However, there was a non-significant 24% relative ⬇️ in worsening HF events 📍In the as-treated analysis, digoxin was associated with a 34% relative risk ⬇️ in the primary outcome 📍Low-dose digoxin was generally safe & well tolerated, including in women & patients with #AFib 📍High study-drug discontinuation rates ➡️ reduced statistical power @escardio @HFA_President @jozinetm #LBCT

🫀In #advanced HF, how do outcomes compare between #HM3 #LVAD & #HTx strategies in middle-aged & older patients? Presented by @NirUrielMD at #HeartFailure26: 📍When survival was measured from treatment, HTx showed higher 2-year survival vs HM3 LVAD in both age groups 📍However, when waitlist time was incorporated, HM3 LVAD therapy outperformed transplant listing in patients aged 50-64 & was numerically favorable in older adults 📍These findings highlight the importance of evaluating real-world treatment pathways, not transplant outcomes alone 📍The role of durable LVAD therapy continues to expand as bridge-to-transplant & destination therapy in carefully selected patients @escardio @HFA_President

The HFA Career Café is back at #HeartFailure26 ☕ This is your chance to connect 1:1 with leading heart failure experts & receive personalised guidance on your career path whether clinical, academic, or research-focused 📚 First come-first served & the space is limited, so don’t miss your chance! 👉 Apply now: escardio.org/events/congress… #HFAyoung @jozinetm @MarcoMetra @escardio @HFA_President #HFA_ESC